The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside

被引:26
|
作者
Pichla, SL [1 ]
Murali, R [1 ]
Burnett, RM [1 ]
机构
[1] WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104
关键词
D O I
10.1006/jsbi.1997.3857
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The GD2 ganglioside is a cell-surface component that appears on the surface of metastatic melanoma cells and is a marker for the progression of the disease. The ME36.1 monoclonal antibody binds to the GD2 ganglioside and has shown potential as a therapeutic antibody. ME36.1 is a possible alternative therapy to radiation, which is often ineffective in late-stage melanoma. The crystal structure of the Fab fragment of ME36.1 has been determined using molecular replacement and refined to an R factor of 20.4% at 2.8 Angstrom resolution. The model has good geometry with root-mean-square deviations of 0.008 Angstrom from ideal bond lengths and 1.7 degrees from ideal bond angles. The crystal structure of the ME36.1 Fab shows that its complementarity determining region forms a groove-shaped binding site rather than the pocket-type observed in other sugar binding Fabs. Molecular modeling has placed a four-residue sugar, representative of GD2, in the antigen binding site. The GD2 sugar moiety is stabilized by a network of hydrogen bonds that define the specificity of ME36.1 toward its antigen. (C) 1997 Academic Press.
引用
收藏
页码:6 / 16
页数:11
相关论文
共 50 条
  • [1] ANTIBODY STRUCTURE STUDIES WITH MELANOMA-ASSOCIATED GD2 GANGLIOSIDE
    PICHLA, SL
    MURALI, R
    KORDOWICZ, M
    BURNETT, RM
    BIOPHYSICAL JOURNAL, 1993, 64 (02) : A57 - A57
  • [2] PRELIMINARY CRYSTALLOGRAPHIC DATA FOR AN FAB TO THE MELANOMA-ASSOCIATED GD2 GANGLIOSIDE, AND THE PURIFICATION OF A SOLUBLE FORM OF THIS ANTIGEN
    PICHLA, SL
    MURALI, R
    BURNETT, RM
    ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1995, 51 : 124 - 126
  • [3] IMMUNOGENICITY OF MELANOMA-ASSOCIATED GANGLIOSIDE-GD2 AND GANGLIOSIDE-GM2 IN CANCER-PATIENTS
    TAI, T
    CAHAN, LD
    IRIE, RF
    MORTON, DL
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1984, 25 (MAR): : 276 - 276
  • [4] Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins
    Yesmin, Farhana
    Bhuiyan, Robiul H.
    Ohmi, Yuhsuke
    Yamamoto, Satoko
    Kaneko, Kei
    Ohkawa, Yuki
    Zhang, Pu
    Hamamura, Kazunori
    Cheung, Nai-Kong V.
    Kotani, Norihiro
    Honke, Koichi
    Okajima, Tetsuya
    Kambe, Mariko
    Tajima, Orie
    Furukawa, Keiko
    Furukawa, Koichi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (01)
  • [5] HUMAN-MELANOMA ANTIGEN AH IS AN AUTOANTIGENIC GANGLIOSIDE RELATED TO GD2
    WATANABE, T
    PUKEL, CS
    TAKEYAMA, H
    LLOYD, KO
    SHIKU, H
    LI, LTC
    TRAVASSOS, LR
    OETTGEN, HF
    OLD, LJ
    JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 156 (06): : 1884 - 1889
  • [6] Genetically engineered anti-ganglioside GD2 antibodies for melanoma immunotherapy
    Fierlbeck, G
    Handgretinger, R
    Rassner, G
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (04) : 718 - 718
  • [7] Chitosan nanoparticles targeted to the tumor-associated ganglioside GD2
    A. A. Zubareva
    A. A. Boyko
    I. V. Kholodenko
    F. N. Rozov
    M. V. Larina
    T. K. Aliev
    I. I. Doronin
    P. A. Vishnyakova
    I. M. Molotkovskaya
    R. V. Kholodenko
    Russian Journal of Bioorganic Chemistry, 2016, 42 : 532 - 545
  • [8] Chitosan nanoparticles targeted to the tumor-associated ganglioside GD2
    Zubareva, A. A.
    Boyko, A. A.
    Kholodenko, I. V.
    Rozov, F. N.
    Larina, M. V.
    Aliev, T. K.
    Doronin, I. I.
    Vishnyakova, P. A.
    Molotkovskaya, I. M.
    Kholodenko, R. V.
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2016, 42 (05) : 532 - 545
  • [9] SHEDDING OF GD2 GANGLIOSIDE IN PATIENTS WITH RETINOBLASTOMA
    PORTOUKALIAN, J
    DAVID, MJ
    GAIN, P
    RICHARD, M
    INTERNATIONAL JOURNAL OF CANCER, 1993, 53 (06) : 948 - 951
  • [10] SHEDDING OF GD2 GANGLIOSIDE BY HUMAN NEUROBLASTOMA
    LADISCH, S
    WU, ZL
    FEIG, S
    ULSH, L
    SCHWARTZ, E
    FLOUTSIS, G
    WILEY, F
    LENARSKY, C
    SEEGER, R
    INTERNATIONAL JOURNAL OF CANCER, 1987, 39 (01) : 73 - 76